Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
JPRN-jRCT2031260265 Asciminib Hydrochloride Chronic phase chronic myeloid leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260265, evaluating Asciminib Hydrochloride in Chronic phase chronic myeloid leukemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07671885 Adjuvant systemic therapy based on pathological findings HR-positive/HER2-low Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07671885, evaluating Adjuvant systemic therapy based on pathological findings in HR-positive/HER2-low Breast Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07670273 Trastuzumab Rezetecan HER2 positive adenocarcinoma of biliary tract Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07670273, evaluating Trastuzumab Rezetecan in HER2 positive adenocarcinoma of biliary tract: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260264 Elecoglipron Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260264, evaluating Elecoglipron in Diabetes Mellitus, Type 2: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260258 Semaglutide (Novo Nordisk) Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260258, evaluating Semaglutide (Novo Nordisk) in Diabetes Mellitus, Type 2: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260261 Dapagliflozin Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260261, evaluating Dapagliflozin in Diabetes Mellitus, Type 2: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260262 Elecoglipron Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260262, evaluating Elecoglipron in Diabetes Mellitus, Type 2: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07671534 Mitomycin Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07671534, evaluating Mitomycin in Locally Advanced Malignant Solid Neoplasm: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07670702 Methylone Stress Disorders, Post-Traumatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07670702, evaluating Methylone in Stress Disorders, Post-Traumatic: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
ChiCTR2600127203 Lisaftoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into ChiCTR2600127203, evaluating Lisaftoclax in Acute Myeloid Leukemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07672262 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07672262, evaluating Venetoclax in Acute Myeloid Leukemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07671378 Sonrotoclax Chronic Lymphocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07671378, evaluating Sonrotoclax in Chronic Lymphocytic Leukemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.